Free Hematology CME

  • FREE

    Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018)

    Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus.

    After completing Multiple Myeloma (MM): Updates from 23rd Annual Congress of EHA (EHA 2018) physicians will better be able to:

    • Summarize the most impactful findings presented at EHA 2018 meeting relating to initial treatment of transplant eligible and ineligible myeloma
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to role of autologous stem cell transplant
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to current role of monoclonal antibodies
    • Summarize the most impactful findings presented at EHA 2018 meeting relating to novel immune therapies

    Target Audience: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 15, 2019
    • Expiration of CME credit: April 15, 2021
  • FREE

    Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding.

    After completing Hemophilia A: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the limitations of annual bleed rate as an epidemiological measure in Hemophilia A
    • Define early prophylaxis in severe hemophilia A and describe its impact on osteochondral damage
    • List evidence-supported benefits of extending clotting factor half lives
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia A, and apply them to patient cases
    • Describe the emerging therapies in the treatment of hemophilia A

     

    Target Audience:

    hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with Hemophilia A.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 04, 2019
    • Expiration of CME credit: March 04, 2021
  • FREE

    Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor

    After completing Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the gene therapy and its anticipated impact on hemophilia B therapy
    • List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
    • Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors

    Target Audience: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 05, 2019
    • Expiration of CME credit: March 05, 2021
  • FREE

    Atypical hemolytic uremic syndrome (aHUS): therapeutic updates and optimizing treatment

    Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.

    After completing this course, you will better be able to:

    • Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
    • Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
    • Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
    • Design an evidence-based treatment plan for a patient with aHUS

    Target Audience: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 10, 2019
    • Expiration of CME credit: July 10, 2021
  • FREE

    ScientiaCME Treatment strategies in Gaucher disease

    At the conclusion of By the end of Treatment strategies in Gaucher disease, you will be able to:
    • Describe the importance of appropriate GD (Gaucher Disease) diagnosis and treatment (use • for bullets)
    • Determine the likelihood of GD using with established diagnosis methods, given a patient case
    • Describe present therapies for the treatment of GD and the literature supporting their use
    • Design a medical plan to treat a patient with GD, taking into account presently available therapies

    Target Audience:
    Physicians focusing on Cardiology, genetic disorders, hematology, oncology, orthopedics, gastroenterology, neurology and pediatrics.

    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: February 12, 2017
    • Expiration of CME credit: February 12, 2019
  • FREE

    Multiple Myeloma (MM): Highlights from the American Society for Clinical Oncology (ASCO) 2018

    This free online CME program covers key learnings around Multiple Myeloma from the American Society for Clinical Oncology 2018 Conference.

    After completing this course, physicians will better be able to:

    • Summarize the most impactful findings presented at ASCO 2018 relating to Multiple myeloma and apply them to patient cases, taking into account any relevant barriers to care.
    • Additional objectives to be dictated by clinical content

    Target Audience: The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 19, 2018
    • Expiration of CME credit: July 19, 2020
  • FREE

    Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.

    After reviewing Congenital Thrombotic Thrombocytopenic Purpura (cTTP) (Upshaw-Schulman syndrome): Therapeutic Updates, Best Practices, and Emerging Therapies physiicians will be able to:

    • Describe the pathophysiology of cTTP such that it might inform treatment mechanisms.
    • Identify diagnostic criteria and differential diagnoses for cTTP
    • Describe current treatment standards for the management of cTTP and apply them to patient cases
    • Describe new and emerging therapies for the treatment of cTTP and the existing literature support its use in practice
    • Evaluate the likelihood cTTP in a patient case and develop a treatment plan

    Target Audience: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 02, 2018
    • Expiration of CME credit: October 02, 2020
  • FREE

    Hemophilia B: Therapeutic Updates, Emerging Therapies, and Barriers to Care

    This free online CME course provides clinical insights about Hemophilia B and helps physicians better treat the condition.

    Topics covered include:

    • Updates in the epidemiology and diagnosis of hemophilia B
    • Current and emerging treatment options for hemophilia B
    • Challenges in care in hemophilia B

    After completing this course, you will better be able to:

    • Describe the pathophysiology of hemophilia B, with an emphasis on characteristics that play a role in determining the staging, prognosis, and diagnosis
    • Describe the benefits of prophylactic vs. on-demand clotting factor regimens in patients with hemophilia and apply them inpatient cases
    • Describe emerging therapies in the treatment of hemophilia B
    • Individualize treatments in patients with hemophilia B by taking into account treatment modalities, recent clinical trial evidence, and barriers to care, including inhibitors

    Target audience: Hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other clinicians with an interest in hemophilia B.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: May 08, 2018
    • Expiration of CME credit: May 08, 2020
  • FREE

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

    By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
    • Recall updates in the staging, prognosis, and diagnosis of MM.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

    Target Audience:
    Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 02, 2017
    • Expiration of CME credit: November 02, 2019